BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled human malaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to assess protective efficacy against heterologous Pf (different from Pf in the vaccine), after fewer doses, and at 24 weeks. METHODS: The trial assessed tolerability, safety, immunogenicity, and protective efficacy of direct venous inoculation (DVI) of 3 or 5 doses of PfSPZ Vaccine in non-immune subjects. RESULTS: Three weeks after final immunization, 5 doses of 2.7 × 105 PfSPZ protected 12 of 13 recipients (92.3% [95% CI: 48.0, 99.8]) against homologous CHMI and 4 of 5 (80.0% [10.4, 99.5]) against heterologous CHMI; 3 doses of 4.5 × 105 PfSPZ protected 13 of 15 (86.7% [35.9, 98.3]) against homologous CHMI. Twenty-four weeks after final immunization, the 5-dose regimen protected 7 of 10 (70.0% [17.3, 93.3]) against homologous and 1 of 10 (10.0% [-35.8, 45.6]) against heterologous CHMI; the 3-dose regimen protected 8 of 14 (57.1% [21.5, 76.6]) against homologous CHMI. All 22 controls developed Pf parasitemia. PfSPZ Vaccine was well tolerated, safe, and easy to administer. No antibody or T cell responses correlated with protection. CONCLUSIONS: We have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects. A 3-dose regimen protected against both 3-week and 24-week homologous CHMI (87% and 57%, respectively) in this population. These results provide a foundation for developing an optimized immunization regimen for preventing malaria. TRIAL REGISTRATION: ClinicalTrials.gov NCT02215707. FUNDING: Support was provided through the US Army Medical Research and Development Command, Military Infectious Diseases Research Program, and the Naval Medical Research Center's Advanced Medical Development Program.
BACKGROUND: A radiation-attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) malaria vaccine, PfSPZ Vaccine, protected 6 of 6 subjects (100%) against homologous Pf (same strain as in the vaccine) controlled humanmalaria infection (CHMI) 3 weeks after 5 doses administered intravenously. The next step was to assess protective efficacy against heterologous Pf (different from Pf in the vaccine), after fewer doses, and at 24 weeks. METHODS: The trial assessed tolerability, safety, immunogenicity, and protective efficacy of direct venous inoculation (DVI) of 3 or 5 doses of PfSPZ Vaccine in non-immune subjects. RESULTS: Three weeks after final immunization, 5 doses of 2.7 × 105 PfSPZ protected 12 of 13 recipients (92.3% [95% CI: 48.0, 99.8]) against homologous CHMI and 4 of 5 (80.0% [10.4, 99.5]) against heterologous CHMI; 3 doses of 4.5 × 105 PfSPZ protected 13 of 15 (86.7% [35.9, 98.3]) against homologous CHMI. Twenty-four weeks after final immunization, the 5-dose regimen protected 7 of 10 (70.0% [17.3, 93.3]) against homologous and 1 of 10 (10.0% [-35.8, 45.6]) against heterologous CHMI; the 3-dose regimen protected 8 of 14 (57.1% [21.5, 76.6]) against homologous CHMI. All 22 controls developed Pfparasitemia. PfSPZ Vaccine was well tolerated, safe, and easy to administer. No antibody or T cell responses correlated with protection. CONCLUSIONS: We have demonstrated for the first time to our knowledge that PfSPZ Vaccine can protect against a 3-week heterologous CHMI in a limited group of malaria-naive adult subjects. A 3-dose regimen protected against both 3-week and 24-week homologous CHMI (87% and 57%, respectively) in this population. These results provide a foundation for developing an optimized immunization regimen for preventing malaria. TRIAL REGISTRATION: ClinicalTrials.gov NCT02215707. FUNDING: Support was provided through the US Army Medical Research and Development Command, Military Infectious Diseases Research Program, and the Naval Medical Research Center's Advanced Medical Development Program.
Authors: D E Neafsey; M Juraska; T Bedford; D Benkeser; C Valim; A Griggs; M Lievens; S Abdulla; S Adjei; T Agbenyega; S T Agnandji; P Aide; S Anderson; D Ansong; J J Aponte; K P Asante; P Bejon; A J Birkett; M Bruls; K M Connolly; U D'Alessandro; C Dobaño; S Gesase; B Greenwood; J Grimsby; H Tinto; M J Hamel; I Hoffman; P Kamthunzi; S Kariuki; P G Kremsner; A Leach; B Lell; N J Lennon; J Lusingu; K Marsh; F Martinson; J T Molel; E L Moss; P Njuguna; C F Ockenhouse; B Ragama Ogutu; W Otieno; L Otieno; K Otieno; S Owusu-Agyei; D J Park; K Pellé; D Robbins; C Russ; E M Ryan; J Sacarlal; B Sogoloff; H Sorgho; M Tanner; T Theander; I Valea; S K Volkman; Q Yu; D Lapierre; B W Birren; P B Gilbert; D F Wirth Journal: N Engl J Med Date: 2015-10-21 Impact factor: 91.245
Authors: Andrew S Ishizuka; Kirsten E Lyke; Adam DeZure; Andrea A Berry; Thomas L Richie; Floreliz H Mendoza; Mary E Enama; Ingelise J Gordon; Lee-Jah Chang; Uzma N Sarwar; Kathryn L Zephir; LaSonji A Holman; Eric R James; Peter F Billingsley; Anusha Gunasekera; Sumana Chakravarty; Anita Manoj; MingLin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Natasha K C; Tooba Murshedkar; Hope DeCederfelt; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Jamie G Saunders; Matthew B Laurens; Christopher V Plowe; Barbara Flynn; William R Whalen; J P Todd; Jay Noor; Srinivas Rao; Kailan Sierra-Davidson; Geoffrey M Lynn; Judith E Epstein; Margaret A Kemp; Gary A Fahle; Sebastian A Mikolajczak; Matthew Fishbaugher; Brandon K Sack; Stefan H I Kappe; Silas A Davidson; Lindsey S Garver; Niklas K Björkström; Martha C Nason; Barney S Graham; Mario Roederer; B Kim Lee Sim; Stephen L Hoffman; Julie E Ledgerwood; Robert A Seder Journal: Nat Med Date: 2016-05-09 Impact factor: 53.440
Authors: Stephen L Hoffman; Lucy M L Goh; Thomas C Luke; Imogene Schneider; Thong P Le; Denise L Doolan; John Sacci; Patricia de la Vega; Megan Dowler; Chris Paul; Daniel M Gordon; Jose A Stoute; L W Preston Church; Martha Sedegah; D Gray Heppner; W Ripley Ballou; Thomas L Richie Journal: J Infect Dis Date: 2002-04-01 Impact factor: 5.226
Authors: S L Hoffman; R Wistar; W R Ballou; M R Hollingdale; R A Wirtz; I Schneider; H A Marwoto; W T Hockmeyer Journal: N Engl J Med Date: 1986-09-04 Impact factor: 91.245
Authors: Stephen L Hoffman; Peter F Billingsley; Eric James; Adam Richman; Mark Loyevsky; Tao Li; Sumana Chakravarty; Anusha Gunasekera; Rana Chattopadhyay; Minglin Li; Richard Stafford; Adriana Ahumada; Judith E Epstein; Martha Sedegah; Sharina Reyes; Thomas L Richie; Kirsten E Lyke; Robert Edelman; Matthew B Laurens; Christopher V Plowe; B Kim Lee Sim Journal: Hum Vaccin Date: 2010-01-21
Authors: J E Egan; S L Hoffman; J D Haynes; J C Sadoff; I Schneider; G E Grau; M R Hollingdale; W R Ballou; D M Gordon Journal: Am J Trop Med Hyg Date: 1993-08 Impact factor: 2.345
Authors: D Walliker; I A Quakyi; T E Wellems; T F McCutchan; A Szarfman; W T London; L M Corcoran; T R Burkot; R Carter Journal: Science Date: 1987-06-26 Impact factor: 47.728
Authors: Robert A Seder; Lee-Jah Chang; Mary E Enama; Kathryn L Zephir; Uzma N Sarwar; Ingelise J Gordon; LaSonji A Holman; Eric R James; Peter F Billingsley; Anusha Gunasekera; Adam Richman; Sumana Chakravarty; Anita Manoj; Soundarapandian Velmurugan; MingLin Li; Adam J Ruben; Tao Li; Abraham G Eappen; Richard E Stafford; Sarah H Plummer; Cynthia S Hendel; Laura Novik; Pamela J M Costner; Floreliz H Mendoza; Jamie G Saunders; Martha C Nason; Jason H Richardson; Jittawadee Murphy; Silas A Davidson; Thomas L Richie; Martha Sedegah; Awalludin Sutamihardja; Gary A Fahle; Kirsten E Lyke; Matthew B Laurens; Mario Roederer; Kavita Tewari; Judith E Epstein; B Kim Lee Sim; Julie E Ledgerwood; Barney S Graham; Stephen L Hoffman Journal: Science Date: 2013-08-08 Impact factor: 47.728
Authors: Laura C Steinhardt; Thomas L Richie; Reuben Yego; Dorcas Akach; Mary J Hamel; Julie R Gutman; Ryan E Wiegand; Elizabeth L Nzuu; Allan Dungani; Natasha Kc; Tooba Murshedkar; L W Preston Church; B Kim Lee Sim; Peter F Billingsley; Eric R James; Yonas Abebe; Simon Kariuki; Aaron M Samuels; Kephas Otieno; Tony Sang; S Patrick Kachur; David Styers; Kelly Schlessman; Ginnie Abarbanell; Stephen L Hoffman; Robert A Seder; Martina Oneko Journal: Clin Infect Dis Date: 2020-08-14 Impact factor: 9.079
Authors: Jean Claude Dejon-Agobe; Ulysse Ateba-Ngoa; Albert Lalremruata; Andreas Homoet; Julie Engelhorn; Odilon Paterne Nouatin; Jean Ronald Edoa; José F Fernandes; Meral Esen; Yoanne Darelle Mouwenda; Eunice M Betouke Ongwe; Marguerite Massinga-Loembe; Stephen L Hoffman; B Kim Lee Sim; Michael Theisen; Peter G Kremsner; Ayôla A Adegnika; Bertrand Lell; Benjamin Mordmüller Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Xin-Xing Gu; Stanley A Plotkin; Kathryn M Edwards; Alessandro Sette; Kingston H G Mills; Ofer Levy; Andrea J Sant; Annie Mo; William Alexander; Kristina T Lu; Christopher E Taylor Journal: Clin Vaccine Immunol Date: 2017-07-05
Authors: Isabelle Zenklusen; Said Jongo; Salim Abdulla; Kamaka Ramadhani; B Kim Lee Sim; Hayley Cardamone; Erika L Flannery; Thao Nguyen; Matthew Fishbaugher; Ryan W J Steel; Will Betz; Nelly Carmago; Sebastian Mikolajczak; Stefan H I Kappe; Stephen L Hoffman; Brandon K Sack; Claudia Daubenberger Journal: J Infect Dis Date: 2018-04-23 Impact factor: 5.226
Authors: Mahamadou S Sissoko; Sara A Healy; Abdoulaye Katile; Freda Omaswa; Irfan Zaidi; Erin E Gabriel; Bourama Kamate; Yacouba Samake; Merepen A Guindo; Amagana Dolo; Amadou Niangaly; Karamoko Niaré; Amatigue Zeguime; Kourane Sissoko; Hama Diallo; Ismaila Thera; Kelly Ding; Michael P Fay; Elise M O'Connell; Thomas B Nutman; Sharon Wong-Madden; Tooba Murshedkar; Adam J Ruben; Minglin Li; Yonas Abebe; Anita Manoj; Anusha Gunasekera; Sumana Chakravarty; B Kim Lee Sim; Peter F Billingsley; Eric R James; Michael Walther; Thomas L Richie; Stephen L Hoffman; Ogobara Doumbo; Patrick E Duffy Journal: Lancet Infect Dis Date: 2017-02-16 Impact factor: 25.071
Authors: Matthew B Laurens; Andrea A Berry; Mark A Travassos; Kathy Strauss; Matthew Adams; Biraj Shrestha; Tao Li; Abraham Eappen; Anita Manoj; Yonas Abebe; Tooba Murshedkar; Anusha Gunasekera; Thomas L Richie; Kirsten E Lyke; Christopher V Plowe; Jessie K Kennedy; Gail E Potter; Gregory A Deye; B K L Sim; Stephen L Hoffman Journal: J Infect Dis Date: 2019-11-06 Impact factor: 5.226